Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Reuter

Showing results (191-200 of 195) with videos related to

Pageof 20
Sort By:
You have reached the last page of results.This site can display upto 195 results.
The Journal of Pharmacology and Experimental Therapeutics|September 1, 2012
Preclinical characterization of ABT-348, a kinase inhibitor targeting the aurora, vascular endothelial growth factor receptor/platelet-derived growth factor receptor, and Src kinase familiesKeith B Glaser, Junling Li, Patrick A Marcotte, et al.
Molecular Cancer Therapeutics|February 28, 2018
Characterization of ABBV-221, a Tumor-Selective EGFR-Targeting Antibody Drug ConjugateAndrew C Phillips, Erwin R Boghaert, Kedar S Vaidya, et al.
Heliyon|September 10, 2024
Navitoclax safety, tolerability, and effect on biomarkers of senescence and neurodegeneration in aged nonhuman primatesEdward F Greenberg, Martin J Voorbach, Alexandra Smith, et al.
Molecular Cancer Therapeutics|May 2, 2006
Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitorDaniel H Albert, Paul Tapang, Terrance J Magoc, et al.
Journal of Medicinal Chemistry|March 9, 2007
Discovery of N-(4-(3-amino-1H-indazol-4-yl)phenyl)-N'-(2-fluoro-5-methylphenyl)urea (ABT-869), a 3-aminoindazole-based orally active multitargeted receptor tyrosine kinase inhibitorYujia Dai, Kresna Hartandi, Zhiqin Ji, et al.
Pageof 20

Showing results (191-200 of 195) with videos related to

Sort By:
Pageof 20
You have reached the last page of results.This site can display upto 195 results.
The Journal of Pharmacology and Experimental Therapeutics|September 1, 2012
Preclinical characterization of ABT-348, a kinase inhibitor targeting the aurora, vascular endothelial growth factor receptor/platelet-derived growth factor receptor, and Src kinase familiesKeith B Glaser, Junling Li, Patrick A Marcotte, et al.
Molecular Cancer Therapeutics|February 28, 2018
Characterization of ABBV-221, a Tumor-Selective EGFR-Targeting Antibody Drug ConjugateAndrew C Phillips, Erwin R Boghaert, Kedar S Vaidya, et al.
Heliyon|September 10, 2024
Navitoclax safety, tolerability, and effect on biomarkers of senescence and neurodegeneration in aged nonhuman primatesEdward F Greenberg, Martin J Voorbach, Alexandra Smith, et al.
Molecular Cancer Therapeutics|May 2, 2006
Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitorDaniel H Albert, Paul Tapang, Terrance J Magoc, et al.
Journal of Medicinal Chemistry|March 9, 2007
Discovery of N-(4-(3-amino-1H-indazol-4-yl)phenyl)-N'-(2-fluoro-5-methylphenyl)urea (ABT-869), a 3-aminoindazole-based orally active multitargeted receptor tyrosine kinase inhibitorYujia Dai, Kresna Hartandi, Zhiqin Ji, et al.
Pageof 20